Co-Phenylcaine Spray: can we improve the taste? A randomised, double-blind, crossover study

2017 ◽  
Vol 132 (2) ◽  
pp. 138-142
Author(s):  
S Bailey ◽  
B Panizza ◽  
P Cabot ◽  
B Wallwork

AbstractObjective:Co-Phenylcaine Forte is a nasal spray routinely prescribed by otolaryngologists in Australia. The taste of Co-Phenylcaine Forte is typically described as unpleasant. This study sought to improve the overall patient experience associated with Co-Phenylcaine Forte by generating a Co-Phenylcaine Forte formulation, referred to as Co-Phenylcaine Zest, which contains an added vanilla flavour and masking agent.Methods:Participants were randomised to receive two actuations of Co-Phenylcaine Forte in each nostril followed by two actuations of Co-Phenylcaine Zest, or vice versa. There was a 6–36-hour washout period between each treatment. After the administration of each spray, participants completed a questionnaire to rate various sensory attributes of each formulation on seven-point ordinal scales. Patients reported their overall formulation preference after receiving both treatments.Results:A total of 86 participants completed the trial. Seventy-four per cent of patients preferred Co-Phenylcaine Zest, 21 per cent preferred Co-Phenylcaine Forte and 5 per cent had no preference (p < 0.001). The satisfaction score associated with Co-Phenylcaine Zest was 1.22 points greater than with Co-Phenylcaine Forte (p < 0.001).Conclusion:A novel formulation of Co-Phenylcaine Forte was created by adding a flavour and a masking agent; this formulation was preferred by most patients.

Cephalalgia ◽  
1987 ◽  
Vol 7 (2) ◽  
pp. 131-133 ◽  
Author(s):  
F Cankat Tulunay ◽  
Onur Karan ◽  
Nursel Aydin ◽  
Adil Culcuoglu ◽  
Adnan Guvener

Ergot derivatives have been used in the treatment of migraine for more than 50 years. We have compared the efficacy of dihydroergotamine (DHE) nasal spray with that of placebo in patients with classic or common migraine attacks. The study was performed in accordance with a double-blind, crossover design. In this study a great placebo effect was observed with a dose of 1.36 mg/attack, and the overall efficacy was rated by the patients to be 41% and 52% for placebo and DHE, respectively.


1979 ◽  
Vol 42 (02) ◽  
pp. 621-625 ◽  
Author(s):  
G G Nenci ◽  
G Agnelli ◽  
M Berrettini ◽  
P Parise ◽  
E Ballatori

SummaryIn a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.


Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 696
Author(s):  
Neus Bosch-Sierra ◽  
Roger Marqués-Cardete ◽  
Aránzazu Gurrea-Martínez ◽  
Carmen Grau-Del Valle ◽  
Clara Talens ◽  
...  

The authors have requested that the following changes be made to their paper [...]


Sign in / Sign up

Export Citation Format

Share Document